Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557786 | 1.00 | KMT2A (0.55) | KMT2ASIGMAR1TP53MDM2LMNA | |
| SCHEMBL5556913 | 0.87 | SIGMAR1 (0.60) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5556907 | 0.87 | SIGMAR1 (0.60) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5557549 | 0.87 | SIGMAR1 (0.68) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5557553 | 0.87 | SIGMAR1 (0.68) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5558029 | 0.81 | SIGMAR1 (0.61) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5558033 | 0.81 | SIGMAR1 (0.61) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5564360 | 0.80 | ALDH1A1 (0.62) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5558858 | 0.80 | ALDH1A1 (0.62) | KMT2ASIGMAR1LMNAALDH1A1MEN1 | |
| SCHEMBL5557480 | 0.80 | DRD4 (0.60) | KMT2ASIGMAR1LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | KMT2A 3291/4885SIGMAR1 61/4885TP53 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.